Hemab Therapeutics

Hemab Therapeutics is at the forefront of biotechnology research, dedicated to developing next-generation therapeutics for bleeding and thrombotic disorders. With a commitment to innovation, Hemab Therapeutics is focused on transforming the treatment landscape for patients with high unmet needs in blood clotting disorders. Hemab Therapeutics is progressing a pipeline of monoclonal and bispecific antibody-based therapeutics.

Headquartered in Copenhagen, with a significant presence at Ole Maaløes Vej 3, 2200 DK, and also located at 101 Main Street, 12th Floor, Cambridge, Massachusetts 02142, US, Hemab Therapeutics operates with a clear strategic vision. The company is dedicated to delivering long-awaited innovations for conditions such as Glanzmann Thrombasthenia, factor VII deficiency, Bernard Soulier Syndrome, Von Willebrand Disease, and other serious disorders.

Hemab Therapeutics is committed to advancing the field of biotechnology and improving patient outcomes through cutting-edge research and development. The information regarding Hemab Therapeutics is being completed with the support of the company’s management to enhance our platform's representation. We invite the manager of Hemab Therapeutics to create a customized and exclusive company showcase and product listing on our platform to further highlight your contributions and offerings to the biotechnology sector.